Literature DB >> 24549739

High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer.

Hui Zhou1, Jian-hua Chen, Jun Hu, Yong-zhong Luo, Fang Li, Ling Xiao, Mei-zuo Zhong.   

Abstract

PURPOSE: Toll-like receptor 5 (TLR5) is a pattern recognition receptor and plays key roles in inflammatory responses against pathogen infection. Recent evidence suggests that TLR5 is expressed in a wide variety of tumors and exhibits either pro-tumor or anti-tumor activities. In this study, we explored expression of TLR5 in the context of non-small-cell lung cancer (NSCLC) and evaluated the effects of TLR5 signaling in NSCLC cells.
METHODS: The lung carcinoma samples were collected from 113 patients diagnosed as NSCLC at Tumor Hospital of Xiangya School of Medicine from January 2005 to December 2008. Immunohistochemistry was performed for TLR5 and the protein expression score was quantified using an established scoring system. Kaplan-Meier survival curves were generated for disease-free survival (DFS) and overall survival (OS) in all patients. TLR5 expression levels were correlated with DFS and OS using univariate and multivariate Cox regression analysis. Expression and subcellular localization of TLR5 were analyzed in NSCLC cell lines including SPC-A1, A549, H1975, and H1299 cells. Activation of TLR5 signaling pathway by flagellin was characterized by western blotting. Effects of flagellin on NSCLC cell proliferation, anchorage-independent growth, migration, and invasion were analyzed by BrdU incorporation assay, soft agar colony formation assay, wound-healing migration assay, and transwell invasion assay, respectively.
RESULTS: High expression of TLR5 was significantly associated with better prognosis in patients with NSCLC. We further demonstrated that activation of TLR5 by flagellin in NSCLC cells inhibited cell proliferation, migration, and invasion in vitro.
CONCLUSION: TLR5 may serve as a potential therapeutic target in NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549739     DOI: 10.1007/s00432-014-1616-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.

Authors:  A Badache; N E Hynes
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

Review 3.  Pattern recognition receptors and inflammation.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

4.  Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.

Authors:  Zhenyu Cai; Amir Sanchez; Zhongcheng Shi; Tingting Zhang; Mingyao Liu; Dekai Zhang
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

5.  Delays in the diagnosis of lung cancer.

Authors:  Peter M Ellis; Rachel Vandermeer
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

6.  Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Katerina D Samara; Katerina M Antoniou; Konstantinos Karagiannis; Georgios Margaritopoulos; Ismini Lasithiotaki; Eleni Koutala; Nikolaos M Siafakas
Journal:  Int J Oncol       Date:  2012-02-15       Impact factor: 5.650

7.  Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immune-compromised hosts.

Authors:  Hiroshi Ishiguro; Takashi Kishimoto; Mitsuko Furuya; Yuichiro Nagai; Toru Watanabe; Hiroshi Ishikura
Journal:  Cancer Immunol Immunother       Date:  2005-04-22       Impact factor: 6.968

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis.

Authors:  Joonas H Kauppila; Antti E Mattila; Tuomo J Karttunen; Tuula Salo
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  Increased expression of Toll-like receptor 5 during progression of cervical neoplasia.

Authors:  W Y Kim; J-W Lee; J-J Choi; C H Choi; T-J Kim; B-G Kim; S Y Song; D-S Bae
Journal:  Int J Gynecol Cancer       Date:  2007-06-22       Impact factor: 3.437

View more
  16 in total

Review 1.  The influence of the commensal microbiota on distal tumor-promoting inflammation.

Authors:  Claire M Buchta Rosean; Melanie R Rutkowski
Journal:  Semin Immunol       Date:  2017-07-04       Impact factor: 11.130

Review 2.  De- "bug"-ing the microbiome in lung cancer.

Authors:  Pakhi Birla; Fyza Y Shaikh
Journal:  Cancer Metastasis Rev       Date:  2022-05-19       Impact factor: 9.237

Review 3.  Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.

Authors:  Eileena F Giurini; Mary Beth Madonna; Andrew Zloza; Kajal H Gupta
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

4.  Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.

Authors:  Elina Levina; Hao Ji; Mengqiang Chen; Mirza Baig; David Oliver; Patrice Ohouo; Chang-uk Lim; Garry Schools; Steven Carmack; Ye Ding; Eugenia V Broude; Igor B Roninson; Ralph Buttyan; Michael Shtutman
Journal:  Oncotarget       Date:  2015-05-30

5.  Roles of toll-like receptors: From inflammation to lung cancer progression.

Authors:  Jinjing Gu; Yi Liu; Bin Xie; Pingping Ye; Jiefan Huang; Zhe Lu
Journal:  Biomed Rep       Date:  2017-12-28

6.  Impact of Genetic Variation in TLR4 3'UTR on NSCLC Genetic Susceptibility.

Authors:  Hongjiao Wu; Hui Gao; Ang Li; Yuning Xie; Zhenxian Jia; Zhenbang Yang; Hongmei Zhang; Zhi Zhang; Xuemei Zhang
Journal:  J Oncol       Date:  2020-04-09       Impact factor: 4.375

7.  Immunohistochemical Analysis of Toll-Like Receptors, MyD88, and TRIF in Human Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.

Authors:  Yasuhiro Nihon-Yanagi; Megumi Wakayama; Naobumi Tochigi; Fumi Saito; Hideaki Ogata; Kazutoshi Shibuya
Journal:  J Thyroid Res       Date:  2021-07-01

8.  p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways.

Authors:  Maria Shatz; Igor Shats; Daniel Menendez; Michael A Resnick
Journal:  Oncotarget       Date:  2015-07-10

9.  Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease.

Authors:  Alison K Bauer; Brad L Upham; Elizabeth A Rondini; Meredith A Tennis; Kalpana Velmuragan; David Wiese
Journal:  Oncotarget       Date:  2017-07-22

10.  NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma.

Authors:  Han Wang; Qingqiong Luo; Xiaodong Feng; Ruiyang Zhang; Jiang Li; Fuxiang Chen
Journal:  BMC Cancer       Date:  2018-05-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.